Yong Sook Lynda Lee, MD
Rheumatology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Looking this up.
Hospitals listed: Community Hospital of the Monterey Peninsula · El Camino Health · Good Samaritan Hospital · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lee’s office at (408) 357-1425 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G64264 · Current
Licensed to practise in California · since 1988 · expires 2027-12-31 · Northeastern Ohio Universities College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$657,474
Medicare paid this office $657,474 for 628 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 123 | $254,378 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $240,671 | None |
| Return visit (30+ min) | 529 | $105,336 | $114 |
| Short return visit (20+ min) | 130 | $14,368 | $82 |
| New patient visit (60+ min) | 68 | $13,560 | $199 |
See all 11 services
| Injection, denosumab, 1 mg | 123 | $254,378 | None |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 18 | $240,671 | None |
| Return visit (30+ min) | 529 | $105,336 | $114 |
| Short return visit (20+ min) | 130 | $14,368 | $82 |
| New patient visit (60+ min) | 68 | $13,560 | $199 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 484 | $11,174 | $15 |
| Injection of drug or substance under skin or into muscle | 177 | $8,895 | $14 |
| Influenza vaccine split virus, preservative free | 13 | $1,064 | $82 |
| Aspiration and/or injection of fluid from large joint | 11 | $771 | $64 |
| Administration of influenza virus vaccine | 15 | $573 | $38 |
| Injection, methylprednisolone acetate, 1 mg | 40 | $444 | None |
Who their Medicare patients are
628 Original Medicare patients in 2024. Average age 75 · Under 65 4% · 85 and older 11% · Women 83% · Also on Medicaid 4% · Health risk score 1.31. At or below the middle of the specialty; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 69% · Coronary heart disease 24% · Diabetes 18% · Depression 18% · Cancer 17% · Chronic kidney disease 16% · Atrial fibrillation 16% · COPD 14% · Heart failure 13% · Stroke 9% · Dementia 5%.
The office billed $3,093,280, Medicare allowed $838,243 and paid $657,474; for 86,624 services of 32 kinds; $500,278 of it was for drugs given in the office and $157,195 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 628 | 86,624 | 75 | 1.31 | $3,093,280 | $657,474 |
| 2023 | 611 | 95,566 | 75 | 1.20 | $3,633,939 | $779,597 |
| 2022 | 614 | 128,754 | 75 | 1.21 | $5,473,060 | $1,196,688 |
| 2021 | 604 | 116,591 | 74 | 1.15 | $5,841,286 | $1,305,086 |
| 2020 | 574 | 104,435 | 74 | 1.21 | $5,148,673 | $1,171,925 |
| 2019 | 562 | 90,800 | 74 | 1.17 | $4,329,003 | $1,034,606 |
| 2018 | 550 | 91,942 | 73 | 1.19 | $4,319,245 | $1,103,832 |
| 2017 | 493 | 82,118 | 73 | 1.16 | $3,918,517 | $994,090 |
| 2016 | 506 | 64,446 | 72 | 1.14 | $2,770,074 | $865,594 |
| 2015 | 447 | 61,150 | 72 | 1.09 | $1,928,705 | $732,621 |
| 2014 | 415 | 32,785 | 73 | 1.06 | $1,266,450 | $593,197 |
| 2013 | 410 | 19,095 | 73 | 1.05 | $961,195 | $445,750 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 23 | $253,948 | None |
| Injection, denosumab, 1 mg | 120 | $207,412 | None |
| Return visit (30+ min) | 504 | $99,738 | $112 |
| New patient visit (60+ min) | 73 | $14,370 | $197 |
| Short return visit (20+ min) | 87 | $9,270 | $81 |
| Injection of drug or substance under skin or into muscle | 172 | $8,168 | $14 |
| Telephone medical discussion with physician, 21-30 minutes | 42 | $6,023 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $4,411 | $68 |
| Influenza vaccine split virus, preservative free | 29 | $2,086 | $72 |
| Administration of influenza virus vaccine | 31 | $1,146 | $37 |
| Injection, methylprednisolone acetate, 40 mg | 26 | $366 | None |
2022: 17 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 20 | $310,651 | None |
| Injection, denosumab, 1 mg | 130 | $224,639 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $178,548 | None |
| Return visit (30+ min) | 513 | $108,002 | $113 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $69,146 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 62 | $13,926 | $71 |
| New patient visit (60+ min) | 61 | $12,397 | $203 |
| Injection of drug or substance under skin or into muscle | 176 | $9,109 | $14 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $8,769 | $149 |
| Short return visit (20+ min) | 76 | $7,680 | $83 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $2,575 | $78 |
| Long return visit (40+ min) | 13 | $2,070 | $159 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,769 | $31 |
| Influenza vaccine split virus, preservative free | 20 | $1,501 | $68 |
| Administration of influenza virus vaccine | 21 | $858 | $37 |
| Injection, zoledronic acid, 1 mg | 30 | $818 | None |
| Injection, methylprednisolone acetate, 40 mg | 23 | $281 | None |
2021: 19 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 23 | $307,887 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 19 | $230,270 | None |
| Injection, denosumab, 1 mg | 124 | $213,474 | None |
| Injection, tocilizumab, 1 mg | 15 | $137,228 | None |
| Return visit (30+ min) | 493 | $104,285 | $116 |
| Injection, golimumab, 1 mg, for intravenous use | 15 | $64,476 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 68 | $14,057 | $74 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $9,310 | $148 |
| New patient visit (60+ min) | 41 | $8,592 | $210 |
| Injection of drug or substance under skin or into muscle | 174 | $7,413 | $13 |
| Telephone medical discussion with physician, 21-30 minutes | 49 | $5,906 | $97 |
| Short return visit (20+ min) | 56 | $5,015 | $85 |
| Influenza vaccine split virus, preservative free | 27 | $1,762 | $65 |
| Aspiration and/or injection of fluid from large joint | 17 | $1,380 | $60 |
| Administration of influenza virus vaccine | 29 | $636 | $22 |
| Injection, zoledronic acid, 1 mg | 15 | $555 | None |
| Injection, methylprednisolone acetate, 40 mg | 25 | $242 | None |
| Injection, methylprednisolone acetate, 80 mg | 11 | $99 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $78 | None |
2020: 19 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 22 | $294,173 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $184,096 | None |
| Injection, denosumab, 1 mg | 119 | $179,256 | None |
| Injection, tocilizumab, 1 mg | 12 | $128,529 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $92,483 | None |
| Return visit (30+ min) | 444 | $75,030 | $94 |
| Telephone medical discussion with physician, 21-30 minutes | 131 | $18,311 | $101 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 48 | $12,001 | $71 |
| New patient visit (60+ min) | 50 | $9,466 | $189 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $8,802 | $142 |
| Injection of drug or substance under skin or into muscle | 163 | $6,226 | $13 |
| Administration of chemotherapy into vein, each additional hour | 17 | $1,947 | $31 |
| Short return visit (20+ min) | 20 | $1,693 | $68 |
| Long return visit (40+ min) | 11 | $1,503 | $125 |
| Influenza vaccine split virus, preservative free | 21 | $1,329 | $60 |
| Aspiration and/or injection of fluid from large joint | 13 | $807 | $54 |
| Administration of influenza virus vaccine | 23 | $501 | $21 |
| Injection, methylprednisolone acetate, 40 mg | 29 | $329 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $71 | None |
2019: 13 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 16 | $249,684 | None |
| Injection, denosumab, 1 mg | 110 | $157,863 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $121,100 | None |
| Return visit (30+ min) | 518 | $101,670 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 40 | $11,143 | $72 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $7,435 | $143 |
| Injection of drug or substance under skin or into muscle | 161 | $7,028 | $15 |
| New patient visit (60+ min) | 33 | $5,856 | $177 |
| Long return visit (40+ min) | 29 | $3,672 | $118 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,574 | $31 |
| Influenza vaccine split virus, preservative free | 18 | $988 | $55 |
| Injection, methylprednisolone acetate, 40 mg | 44 | $555 | None |
| Administration of influenza virus vaccine | 25 | $513 | $21 |
2018: 15 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 17 | $297,534 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $220,062 | None |
| Injection, denosumab, 1 mg | 99 | $126,207 | None |
| Return visit (30+ min) | 484 | $92,141 | $95 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 40 | $12,306 | $70 |
| Injection of drug or substance under skin or into muscle | 149 | $8,406 | $19 |
| New patient visit (60+ min) | 36 | $6,872 | $191 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $3,691 | $148 |
| Short return visit (20+ min) | 42 | $3,547 | $64 |
| Long return visit (40+ min) | 27 | $3,535 | $126 |
| New patient visit (45+ min) | 20 | $2,816 | $141 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $1,564 | $20 |
| Aspiration and/or injection of fluid from large joint | 15 | $875 | $46 |
| Administration of chemotherapy into vein, each additional hour | 11 | $791 | $32 |
| Injection, methylprednisolone acetate, 40 mg | 42 | $480 | None |
2017: 15 services
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $232,264 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 13 | $229,066 | None |
| Injection, denosumab, 1 mg | 76 | $92,462 | None |
| Return visit (30+ min) | 444 | $82,013 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $14,231 | $67 |
| Injection of drug or substance under skin or into muscle | 120 | $9,379 | $24 |
| Short return visit (20+ min) | 53 | $5,728 | $62 |
| New patient visit (60+ min) | 27 | $4,140 | $153 |
| Long return visit (40+ min) | 30 | $3,590 | $112 |
| New patient visit (45+ min) | 25 | $3,252 | $130 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $2,112 | $17 |
| X-ray of hand, minimum of 3 views | 16 | $654 | $23 |
| Administration of influenza virus vaccine | 20 | $646 | $32 |
| Influenza vaccine split virus, preservative free | 11 | $529 | $48 |
| Injection, methylprednisolone acetate, 40 mg | 37 | $376 | None |
2016: 22 services
| Injection, infliximab, excludes biosimilar, 10 mg | 14 | $239,953 | None |
| Return visit (30+ min) | 460 | $86,003 | $93 |
| Injection, denosumab, 1 mg | 60 | $69,144 | None |
| New patient visit (60+ min) | 62 | $11,310 | $182 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 29 | $10,115 | $67 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 56 | $10,033 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 13 | $7,312 | $122 |
| Short return visit (20+ min) | 53 | $4,530 | $69 |
| Injection of drug or substance under skin or into muscle | 97 | $4,472 | $24 |
| Long return visit (40+ min) | 27 | $3,977 | $133 |
| New patient visit (45+ min) | 18 | $2,737 | $152 |
| Administration of chemotherapy into vein, each additional hour | 13 | $1,899 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,478 | $18 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 21 | $931 | $16 |
| X-ray of hand, minimum of 3 views | 20 | $921 | $27 |
| Administration of influenza virus vaccine | 25 | $792 | $32 |
| X-ray of lower and sacral spine, minimum of 4 views | 17 | $714 | $42 |
| X-ray of knee, 3 views | 15 | $596 | $30 |
| Injection, methylprednisolone acetate, 40 mg | 50 | $519 | None |
| X-ray of shoulder, minimum of 2 views | 12 | $340 | $24 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 19 | $224 | $12 |
| Infusion, normal saline solution, 250 cc | 29 | $53 | None |
2015: 18 services
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $263,543 | None |
| Return visit (30+ min) | 418 | $80,275 | $91 |
| Injection, denosumab, 1 mg | 51 | $55,475 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 64 | $17,414 | $76 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $13,733 | $135 |
| New patient visit (60+ min) | 41 | $7,561 | $184 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $6,449 | $70 |
| Administration of chemotherapy into vein, each additional hour | 16 | $3,107 | $28 |
| Long return visit (40+ min) | 21 | $2,883 | $125 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $1,708 | $18 |
| Short return visit (20+ min) | 27 | $1,461 | $49 |
| Injection of drug or substance under skin or into muscle | 39 | $1,235 | $23 |
| X-ray of hand, minimum of 3 views | 19 | $909 | $28 |
| Administration of influenza virus vaccine | 23 | $731 | $32 |
| X-ray of knee, 3 views | 14 | $570 | $32 |
| Injection, methylprednisolone acetate, 40 mg | 47 | $324 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 23 | $271 | $12 |
| Infusion, normal saline solution, 250 cc | 30 | $65 | None |
2014: 22 services
| Injection, infliximab, excludes biosimilar, 10 mg | 19 | $274,887 | None |
| Return visit (30+ min) | 386 | $76,874 | $91 |
| Injection, denosumab, 1 mg | 40 | $42,445 | None |
| Insertion of needle or tube into artery of arm or leg | 28 | $33,202 | $274 |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $14,249 | $128 |
| Administration of chemotherapy into vein, each additional hour | 19 | $5,832 | $28 |
| Insertion of artery tube for prolonged infusion | 19 | $5,684 | $114 |
| New patient visit (60+ min) | 26 | $4,506 | $173 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 35 | $4,262 | $55 |
| Injection of drug or substance under skin or into muscle | 86 | $4,067 | $24 |
| New patient visit (45+ min) | 23 | $2,909 | $126 |
| Short return visit (20+ min) | 28 | $2,180 | $68 |
| Long return visit (40+ min) | 17 | $1,691 | $99 |
| X-ray of hand, minimum of 3 views | 17 | $783 | $25 |
| Aspiration and/or injection of fluid from large joint | 12 | $763 | $51 |
| Administration of influenza virus vaccine | 23 | $716 | $31 |
| X-ray of lower and sacral spine, minimum of 4 views | 16 | $569 | $36 |
| X-ray of ribs of one side of body, minimum of 2 views | 12 | $479 | $30 |
| X-ray of shoulder, minimum of 2 views | 13 | $402 | $22 |
| Injection, methylprednisolone acetate, 40 mg | 56 | $398 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 24 | $362 | $15 |
| Infusion, normal saline solution, 250 cc | 30 | $43 | None |
2013: 18 services
| Return visit (30+ min) | 385 | $79,364 | $92 |
| Insertion of needle or tube into artery of arm or leg | 28 | $29,382 | $297 |
| Injection, denosumab, 1 mg | 22 | $20,023 | None |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $12,494 | $144 |
| Insertion of artery tube for prolonged infusion | 21 | $4,875 | $113 |
| New patient visit (60+ min) | 25 | $4,673 | $187 |
| New patient visit (45+ min) | 28 | $4,207 | $150 |
| Long return visit (40+ min) | 30 | $4,137 | $125 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $3,645 | $74 |
| Injection of drug or substance under skin or into muscle | 67 | $3,103 | $25 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,321 | $51 |
| X-ray of hand, minimum of 3 views | 21 | $974 | $26 |
| Administration of influenza virus vaccine | 25 | $803 | $32 |
| X-ray of knee, 3 views | 14 | $519 | $31 |
| X-ray of lower and sacral spine, minimum of 4 views | 11 | $399 | $36 |
| Injection, methylprednisolone acetate, 40 mg | 58 | $376 | None |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 25 | $366 | $15 |
| Infusion, normal saline solution, 250 cc | 27 | $16 | None |
Drugs they prescribed that Part D paid
$1,983,321
Pharmacies billed $1,983,321 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 18% of their Part D prescriptions (509 of 2,815) in 2024. A higher opioid share than 9 in 10 peers; the typical rheumatology clinician is at 3%. Long-acting opioids: 7% of their opioid prescriptions.
2,513 generic and fewer than 11 brand-name prescriptions · $1,983,321 in drug cost · 12 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 34 | $532,388 | $15,658 |
| Enbrel | 33 | $266,892 | $8,088 |
| Enbrel Sureclick | 34 | $247,845 | $7,290 |
| Humira(Cf) | 16 | $108,547 | $6,784 |
| Enbrel Mini | 13 | $93,443 | $7,188 |
See all 47 drugs
| Humira(Cf) | 34 | $532,388 | $15,658 |
| Enbrel | 33 | $266,892 | $8,088 |
| Enbrel Sureclick | 34 | $247,845 | $7,290 |
| Humira(Cf) | 16 | $108,547 | $6,784 |
| Enbrel Mini | 13 | $93,443 | $7,188 |
| Orencia | 14 | $90,418 | $6,458 |
| Cosentyx Sensoready (2 Pens) | 12 | $86,041 | $7,170 |
| Kevzara | 13 | $57,763 | $4,443 |
| Teriparatide | 22 | $46,725 | $2,124 |
| Tymlos | 13 | $33,102 | $2,546 |
| Plaquenil | 16 | $32,284 | $2,018 |
| Hydroxychloroquine Sulfate | 391 | $26,447 | $68 |
| Hydrocodone-Acetaminophen | 228 | $11,762 | $52 |
| Cevimeline | 34 | $10,703 | $315 |
| Methotrexate | 147 | $6,972 | $47 |
| Celecoxib | 161 | $6,931 | $43 |
| Leucovorin | 56 | $5,227 | $93 |
| Lidocaine | 24 | $5,127 | $214 |
| Prednisone | 230 | $3,633 | $16 |
| Risedronate | 28 | $3,162 | $113 |
| Fentanyl | 13 | $2,169 | $167 |
| Gabapentin | 118 | $1,984 | $17 |
| Tramadol Hcl Er | 18 | $1,858 | $103 |
| Azathioprine | 24 | $1,629 | $68 |
| Tramadol | 134 | $1,518 | $11 |
| Omega-3 Acid Ethyl Esters | 12 | $1,452 | $121 |
| Alendronate | 146 | $1,264 | $9 |
| Leflunomide | 25 | $1,152 | $46 |
| Colchicine | 16 | $1,102 | $69 |
| Oxycodone-Acetaminophen | 38 | $1,075 | $28 |
| Acetaminophen-Codeine | 46 | $1,024 | $22 |
| Duloxetine | 44 | $1,008 | $23 |
| Pregabalin | 31 | $995 | $32 |
| Trazodone | 35 | $937 | $27 |
| Allopurinol | 72 | $778 | $11 |
| Morphine Sulfate | 14 | $621 | $44 |
| Methylprednisolone | 24 | $607 | $25 |
| Cyclobenzaprine | 29 | $532 | $18 |
| Diclofenac | 23 | $342 | $15 |
| Methotrexate | 17 | $330 | $19 |
| Meloxicam | 37 | $329 | $9 |
| Folic Acid | 17 | $277 | $16 |
| Tramadol Hcl-Acetaminophen | 11 | $151 | $14 |
| Zolpidem | 41 | $145 | $4 |
| Modafinil | 11 | $134 | $12 |
| Amlodipine Besylate | 11 | $51 | $5 |
| Diazepam | 13 | $28 | $2 |
Year by year
| 2024 | 2,815 | 465 | 18% (509) | None | $1,983,321 |
| 2023 | 2,653 | 415 | 16% (425) | 11% | $2,105,183 |
| 2022 | 2,457 | 388 | 17% (410) | 10% | $1,653,567 |
| 2021 | 2,414 | 369 | 17% (415) | None | $1,604,851 |
| 2020 | 2,449 | 342 | 18% (438) | 12% | $1,328,951 |
| 2019 | 2,327 | 383 | 19% (433) | 16% | $1,457,678 |
| 2018 | 2,151 | 348 | 17% (375) | 18% | $1,584,906 |
| 2017 | 2,075 | 303 | 15% (315) | 21% | $1,386,546 |
| 2016 | 1,815 | 271 | 15% (273) | 30% | $1,116,123 |
| 2015 | 1,813 | 254 | 15% (273) | 30% | $929,612 |
| 2014 | 1,883 | 252 | 22% (417) | 29% | $690,695 |
| 2013 | 1,679 | 212 | 23% (388) | None | $480,086 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 47 drugs
| Humira(Cf) | 19 | $536,546 | $28,239 |
| Enbrel Sureclick | 43 | $318,844 | $7,415 |
| Enbrel | 23 | $144,050 | $6,263 |
| Orencia | 15 | $87,893 | $5,860 |
| Enbrel Mini | 12 | $81,214 | $6,768 |
| Tymlos | 27 | $76,078 | $2,818 |
| Cosentyx Sensoready (2 Pens) | 11 | $73,714 | $6,701 |
| Xeljanz | 11 | $65,684 | $5,971 |
| Hydroxychloroquine Sulfate | 352 | $28,233 | $80 |
| Plaquenil | 12 | $25,429 | $2,119 |
| Cevimeline | 41 | $12,501 | $305 |
| Hydrocodone-Acetaminophen | 184 | $10,713 | $58 |
| Celecoxib | 185 | $8,506 | $46 |
| Methotrexate | 140 | $7,223 | $52 |
| Lidocaine | 18 | $5,809 | $323 |
| Gabapentin | 140 | $3,273 | $23 |
| Prednisone | 231 | $3,080 | $13 |
| Duloxetine | 50 | $3,008 | $60 |
| Pregabalin | 44 | $2,067 | $47 |
| Leucovorin | 36 | $1,754 | $49 |
| Fentanyl | 12 | $1,669 | $139 |
| Alendronate | 127 | $1,616 | $13 |
| Pilocarpine | 15 | $1,596 | $106 |
| Omega-3 Acid Ethyl Esters | 11 | $1,590 | $145 |
| Risedronate | 12 | $1,534 | $128 |
| Tramadol | 124 | $1,399 | $11 |
| Azathioprine | 17 | $1,109 | $65 |
| Oxycodone-Acetaminophen | 23 | $1,025 | $45 |
| Nitro-Bid | 12 | $995 | $83 |
| Allopurinol | 74 | $948 | $13 |
| Acetaminophen-Codeine | 37 | $788 | $21 |
| Trazodone | 27 | $764 | $28 |
| Methylprednisolone | 21 | $636 | $30 |
| Leflunomide | 14 | $633 | $45 |
| Morphine Sulfate | 11 | $486 | $44 |
| Methotrexate | 11 | $410 | $37 |
| Diclofenac | 21 | $387 | $18 |
| Tramadol Hcl-Acetaminophen | 13 | $228 | $18 |
| Zolpidem | 30 | $185 | $6 |
| Cyclobenzaprine | 19 | $185 | $10 |
| Meloxicam | 36 | $173 | $5 |
| Oxaprozin | 12 | $172 | $14 |
| Folic Acid | 26 | $150 | $6 |
| Ibuprofen | 13 | $120 | $9 |
| Fluoxetine | 11 | $51 | $5 |
| Alprazolam | 12 | $41 | $3 |
| Diazepam | 15 | $35 | $2 |
2022: 41 drugs
| Humira(Cf) | 24 | $492,273 | $20,511 |
| Enbrel Sureclick | 48 | $325,971 | $6,791 |
| Enbrel | 26 | $131,274 | $5,049 |
| Tymlos | 47 | $114,998 | $2,447 |
| Orencia | 14 | $77,392 | $5,528 |
| Cosentyx Pen (2 Pens) | 12 | $74,418 | $6,201 |
| Hydroxychloroquine Sulfate | 361 | $30,672 | $85 |
| Celecoxib | 165 | $11,325 | $69 |
| Hydrocodone-Acetaminophen | 179 | $10,449 | $58 |
| Cevimeline | 41 | $9,169 | $224 |
| Lidocaine | 12 | $7,475 | $623 |
| Methotrexate | 100 | $6,916 | $69 |
| Gabapentin | 143 | $5,235 | $37 |
| Prednisone | 236 | $4,818 | $20 |
| Pregabalin | 41 | $4,209 | $103 |
| Leflunomide | 17 | $2,541 | $149 |
| Colchicine | 13 | $2,286 | $176 |
| Tramadol | 141 | $1,957 | $14 |
| Omega-3 Acid Ethyl Esters | 16 | $1,850 | $116 |
| Leucovorin | 37 | $1,762 | $48 |
| Azathioprine | 21 | $1,544 | $74 |
| Fentanyl | 12 | $1,443 | $120 |
| Duloxetine | 35 | $1,324 | $38 |
| Alendronate | 102 | $1,030 | $10 |
| Oxycodone-Acetaminophen | 13 | $1,014 | $78 |
| Allopurinol | 66 | $907 | $14 |
| Risedronate | 11 | $764 | $69 |
| Methotrexate | 20 | $538 | $27 |
| Trazodone | 21 | $498 | $24 |
| Cyclobenzaprine | 35 | $466 | $13 |
| Acetaminophen-Codeine | 27 | $446 | $17 |
| Diclofenac | 17 | $417 | $25 |
| Methylprednisolone | 18 | $400 | $22 |
| Tramadol Hcl-Acetaminophen | 12 | $271 | $23 |
| Sulfasalazine | 12 | $230 | $19 |
| Oxaprozin | 11 | $154 | $14 |
| Folic Acid | 16 | $134 | $8 |
| Zolpidem | 29 | $120 | $4 |
| Meloxicam | 24 | $108 | $4 |
| Clonazepam | 13 | $53 | $4 |
| Alprazolam | 12 | $36 | $3 |
2021: 44 drugs
| Humira(Cf) | 23 | $505,528 | $21,979 |
| Enbrel Sureclick | 40 | $273,725 | $6,843 |
| Enbrel | 30 | $147,781 | $4,926 |
| Cosentyx Pen (2 Pens) | 15 | $98,747 | $6,583 |
| Orencia | 13 | $66,592 | $5,122 |
| Xeljanz | 11 | $57,769 | $5,252 |
| Hydroxychloroquine Sulfate | 404 | $40,360 | $100 |
| Tymlos | 15 | $33,511 | $2,234 |
| Hydrocodone-Acetaminophen | 148 | $10,468 | $71 |
| Lidocaine | 13 | $9,057 | $697 |
| Cevimeline | 43 | $8,750 | $203 |
| Celecoxib | 153 | $8,505 | $56 |
| Methotrexate | 110 | $8,431 | $77 |
| Savella | 11 | $6,830 | $621 |
| Prednisone | 222 | $5,188 | $23 |
| Pregabalin | 27 | $4,121 | $153 |
| Gabapentin | 131 | $3,777 | $29 |
| Febuxostat | 12 | $3,208 | $267 |
| Colchicine | 18 | $3,087 | $172 |
| Azathioprine | 22 | $2,526 | $115 |
| Leflunomide | 19 | $2,441 | $128 |
| Omega-3 Acid Ethyl Esters | 11 | $2,026 | $184 |
| Tramadol | 150 | $1,997 | $13 |
| Leucovorin | 37 | $1,925 | $52 |
| Tramadol Hcl Er | 20 | $1,386 | $69 |
| Duloxetine | 30 | $1,254 | $42 |
| Alendronate | 92 | $1,221 | $13 |
| Diclofenac | 21 | $1,211 | $58 |
| Allopurinol | 60 | $1,034 | $17 |
| Oxycodone-Acetaminophen | 19 | $1,002 | $53 |
| Cyclobenzaprine | 42 | $803 | $19 |
| Clobetasol Propionate | 12 | $731 | $61 |
| Acetaminophen-Codeine | 33 | $681 | $21 |
| Fentanyl | 12 | $466 | $39 |
| Trazodone | 11 | $407 | $37 |
| Sulfasalazine | 12 | $351 | $29 |
| Methotrexate | 14 | $349 | $25 |
| Tramadol Hcl-Acetaminophen | 18 | $344 | $19 |
| Warfarin | 11 | $314 | $29 |
| Meloxicam | 32 | $311 | $10 |
| Oxaprozin | 13 | $282 | $22 |
| Clonazepam | 19 | $180 | $9 |
| Lorazepam | 11 | $102 | $9 |
| Zolpidem | 24 | $83 | $3 |
2020: 40 drugs
| Humira(Cf) | 22 | $476,118 | $21,642 |
| Enbrel Sureclick | 32 | $243,417 | $7,607 |
| Enbrel | 25 | $153,348 | $6,134 |
| Orencia | 18 | $87,460 | $4,859 |
| Hydroxychloroquine Sulfate | 423 | $49,029 | $116 |
| Plaquenil | 14 | $18,447 | $1,318 |
| Celecoxib | 147 | $12,997 | $88 |
| Lidocaine | 22 | $11,960 | $544 |
| Cevimeline | 47 | $9,855 | $210 |
| Methotrexate | 120 | $8,892 | $74 |
| Colchicine | 22 | $7,588 | $345 |
| Hydrocodone-Acetaminophen | 147 | $7,339 | $50 |
| Pregabalin | 32 | $4,785 | $150 |
| Prednisone | 200 | $4,470 | $22 |
| Leflunomide | 20 | $3,888 | $194 |
| Risedronate | 12 | $2,815 | $235 |
| Gabapentin | 115 | $2,774 | $24 |
| Diclofenac | 36 | $2,728 | $76 |
| Azathioprine | 29 | $2,515 | $87 |
| Tramadol | 181 | $2,063 | $11 |
| Leucovorin | 32 | $1,541 | $48 |
| Allopurinol | 81 | $1,447 | $18 |
| Alendronate | 115 | $1,292 | $11 |
| Fentanyl | 12 | $1,271 | $106 |
| Tramadol Hcl Er | 21 | $1,203 | $57 |
| Oxycodone-Acetaminophen | 24 | $1,024 | $43 |
| Duloxetine | 23 | $932 | $41 |
| Clonazepam | 24 | $671 | $28 |
| Cyclobenzaprine | 51 | $668 | $13 |
| Mycophenolate Mofetil | 11 | $490 | $45 |
| Warfarin | 16 | $458 | $29 |
| Trazodone | 15 | $399 | $27 |
| Acetaminophen-Codeine | 24 | $388 | $16 |
| Methotrexate | 16 | $332 | $21 |
| Oxaprozin | 12 | $316 | $26 |
| Methylprednisolone | 17 | $285 | $17 |
| Meloxicam | 41 | $258 | $6 |
| Tramadol Hcl-Acetaminophen | 14 | $251 | $18 |
| Zolpidem | 25 | $70 | $3 |
| Insulin | 11 | $50 | $5 |
2019: 42 drugs
| Humira(Cf) | 19 | $312,651 | $16,455 |
| Enbrel Sureclick | 34 | $282,351 | $8,304 |
| Enbrel | 32 | $182,437 | $5,701 |
| Orencia | 25 | $114,001 | $4,560 |
| Forteo | 23 | $91,372 | $3,973 |
| Orencia Clickject | 12 | $51,518 | $4,293 |
| Hydroxychloroquine Sulfate | 309 | $41,607 | $135 |
| Savella | 21 | $14,316 | $682 |
| Celecoxib | 103 | $10,664 | $104 |
| Hydrocodone-Acetaminophen | 150 | $9,653 | $64 |
| Methotrexate | 120 | $7,301 | $61 |
| Colchicine | 17 | $6,788 | $399 |
| Lidocaine | 25 | $6,522 | $261 |
| Cevimeline | 25 | $6,395 | $256 |
| Diclofenac | 44 | $4,804 | $109 |
| Prednisone | 203 | $3,767 | $19 |
| Tramadol | 181 | $2,895 | $16 |
| Risedronate | 13 | $2,875 | $221 |
| Leflunomide | 11 | $2,697 | $245 |
| Gabapentin | 109 | $2,615 | $24 |
| Chloroquine Phosphate | 17 | $2,239 | $132 |
| Leucovorin | 38 | $1,981 | $52 |
| Narcan | 14 | $1,786 | $128 |
| Allopurinol | 83 | $1,701 | $20 |
| Tramadol Hcl-Acetaminophen | 13 | $1,194 | $92 |
| Duloxetine | 26 | $1,035 | $40 |
| Oxycodone Hcl-Aspirin | 11 | $1,013 | $92 |
| Azathioprine | 14 | $987 | $71 |
| Oxycodone-Acetaminophen | 23 | $875 | $38 |
| Alendronate | 88 | $852 | $10 |
| Trazodone | 19 | $483 | $25 |
| Acetaminophen-Codeine | 26 | $466 | $18 |
| Warfarin | 16 | $465 | $29 |
| Cyclobenzaprine | 39 | $403 | $10 |
| Methocarbamol | 22 | $380 | $17 |
| Methylprednisolone | 19 | $373 | $20 |
| Methotrexate | 23 | $360 | $16 |
| Sulfasalazine | 11 | $335 | $30 |
| Meloxicam | 26 | $252 | $10 |
| Carisoprodol | 11 | $223 | $20 |
| Zolpidem | 12 | $147 | $12 |
| Clonazepam | 15 | $114 | $8 |
2018: 43 drugs
| Humira | 23 | $358,126 | $15,571 |
| Enbrel Sureclick | 35 | $310,473 | $8,871 |
| Forteo | 43 | $157,178 | $3,655 |
| Enbrel | 22 | $107,383 | $4,881 |
| Orencia | 23 | $98,836 | $4,297 |
| Orencia Clickject | 14 | $57,575 | $4,113 |
| Hydroxychloroquine Sulfate | 300 | $46,822 | $156 |
| Lyrica | 20 | $21,155 | $1,058 |
| Celecoxib | 141 | $18,164 | $129 |
| Methotrexate | 140 | $12,077 | $86 |
| Savella | 13 | $10,898 | $838 |
| Cevimeline | 27 | $9,385 | $348 |
| Lidocaine | 27 | $8,786 | $325 |
| Hydrocodone-Acetaminophen | 142 | $8,210 | $58 |
| Leflunomide | 24 | $5,606 | $234 |
| Risedronate | 22 | $4,677 | $213 |
| Voltaren | 18 | $4,501 | $250 |
| Prednisone | 160 | $3,202 | $20 |
| Tramadol | 130 | $2,766 | $21 |
| Gabapentin | 89 | $2,639 | $30 |
| Diclofenac | 24 | $2,074 | $86 |
| Leucovorin | 33 | $1,951 | $59 |
| Meperidine | 11 | $1,797 | $163 |
| Fentanyl | 12 | $1,693 | $141 |
| Allopurinol | 82 | $1,629 | $20 |
| Tramadol Hcl-Acetaminophen | 14 | $1,589 | $113 |
| Chloroquine Phosphate | 15 | $1,111 | $74 |
| Oxycodone-Acetaminophen | 24 | $1,020 | $43 |
| Warfarin | 19 | $906 | $48 |
| Oxycodone Hcl-Aspirin | 13 | $810 | $62 |
| Duloxetine | 14 | $720 | $51 |
| Azathioprine | 11 | $522 | $47 |
| Alendronate | 72 | $508 | $7 |
| Acetaminophen-Codeine | 16 | $419 | $26 |
| Trazodone | 20 | $343 | $17 |
| Methylprednisolone | 23 | $329 | $14 |
| Methotrexate | 22 | $276 | $13 |
| Cyclobenzaprine | 14 | $175 | $12 |
| Meloxicam | 11 | $137 | $12 |
| Zolpidem | 11 | $134 | $12 |
| Pantoprazole | 11 | $128 | $12 |
| Temazepam | 13 | $32 | $2 |
| Insulin | 11 | $30 | $3 |
2017: 44 drugs
| Humira | 22 | $252,938 | $11,497 |
| Enbrel Sureclick | 36 | $249,727 | $6,937 |
| Orencia | 22 | $143,605 | $6,528 |
| Forteo | 27 | $111,891 | $4,144 |
| Enbrel | 20 | $88,788 | $4,439 |
| Hydroxychloroquine Sulfate | 309 | $66,376 | $215 |
| Cimzia | 12 | $48,241 | $4,020 |
| Celecoxib | 119 | $16,202 | $136 |
| Lyrica | 15 | $14,214 | $948 |
| Methotrexate | 158 | $14,063 | $89 |
| Colcrys | 21 | $12,728 | $606 |
| Lidocaine | 27 | $12,495 | $463 |
| Savella | 19 | $11,489 | $605 |
| Uloric | 19 | $10,600 | $558 |
| Leflunomide | 33 | $10,517 | $319 |
| Hydrocodone-Acetaminophen | 108 | $7,226 | $67 |
| Risedronate | 23 | $6,297 | $274 |
| Voltaren | 21 | $4,632 | $221 |
| Diclofenac | 27 | $3,916 | $145 |
| Cevimeline | 13 | $3,879 | $298 |
| Mycophenolate Mofetil | 15 | $3,807 | $254 |
| Gabapentin | 98 | $3,643 | $37 |
| Prednisone | 178 | $3,600 | $20 |
| Tramadol | 113 | $2,744 | $24 |
| Meperidine | 12 | $1,975 | $165 |
| Fentanyl | 14 | $1,654 | $118 |
| Allopurinol | 51 | $1,323 | $26 |
| Chloroquine Phosphate | 13 | $1,314 | $101 |
| Leucovorin | 27 | $1,113 | $41 |
| Azathioprine | 14 | $1,069 | $76 |
| Duloxetine | 14 | $1,031 | $74 |
| Tramadol Hcl-Acetaminophen | 16 | $1,005 | $63 |
| Warfarin | 20 | $826 | $41 |
| Oxycodone Hcl-Aspirin | 12 | $821 | $68 |
| Oxycodone-Acetaminophen | 13 | $592 | $46 |
| Methylprednisolone | 22 | $522 | $24 |
| Alendronate | 71 | $512 | $7 |
| Acetaminophen-Codeine | 13 | $481 | $37 |
| Nabumetone | 11 | $477 | $43 |
| Trazodone | 18 | $400 | $22 |
| Eszopiclone | 17 | $272 | $16 |
| Methotrexate | 19 | $213 | $11 |
| Meloxicam | 12 | $109 | $9 |
| Insulin | 12 | $55 | $5 |
2016: 34 drugs
| Enbrel | 51 | $259,143 | $5,081 |
| Humira | 43 | $233,821 | $5,438 |
| Orencia | 43 | $215,906 | $5,021 |
| Forteo | 19 | $65,836 | $3,465 |
| Hydroxychloroquine Sulfate | 264 | $55,325 | $210 |
| Celecoxib | 106 | $16,409 | $155 |
| Savella | 33 | $12,409 | $376 |
| Lidocaine | 28 | $11,805 | $422 |
| Lyrica | 21 | $10,520 | $501 |
| Methotrexate | 145 | $9,541 | $66 |
| Hydrocodone-Acetaminophen | 96 | $8,328 | $87 |
| Cevimeline | 13 | $7,222 | $556 |
| Leflunomide | 26 | $5,978 | $230 |
| Risedronate | 17 | $5,687 | $335 |
| Voltaren | 27 | $5,136 | $190 |
| Prednisone | 172 | $3,353 | $19 |
| Gabapentin | 93 | $3,087 | $33 |
| Diclofenac | 21 | $2,513 | $120 |
| Tramadol Hcl-Acetaminophen | 22 | $2,350 | $107 |
| Tramadol | 93 | $2,334 | $25 |
| Meperidine | 13 | $2,042 | $157 |
| Chloroquine Phosphate | 12 | $1,403 | $117 |
| Fentanyl | 11 | $1,102 | $100 |
| Allopurinol | 51 | $1,047 | $21 |
| Azathioprine | 14 | $829 | $59 |
| Acetaminophen-Codeine | 11 | $638 | $58 |
| Leucovorin | 18 | $622 | $35 |
| Oxycodone Hcl-Aspirin | 12 | $426 | $36 |
| Warfarin | 16 | $407 | $25 |
| Alendronate | 37 | $331 | $9 |
| Methylprednisolone | 15 | $306 | $20 |
| Trazodone | 13 | $231 | $18 |
| Methotrexate | 13 | $151 | $12 |
| Insulin | 15 | $35 | $2 |
2015: 37 drugs
| Enbrel | 40 | $186,179 | $4,654 |
| Orencia | 44 | $152,292 | $3,461 |
| Humira | 24 | $142,217 | $5,926 |
| Humira | 32 | $122,501 | $3,828 |
| Forteo | 18 | $59,695 | $3,316 |
| Hydroxychloroquine Sulfate | 204 | $53,491 | $262 |
| Lidocaine | 28 | $17,448 | $623 |
| Celecoxib | 72 | $15,822 | $220 |
| Celebrex | 26 | $15,750 | $606 |
| Lyrica | 31 | $12,021 | $388 |
| Methotrexate | 145 | $11,336 | $78 |
| Hydrocodone-Acetaminophen | 101 | $9,021 | $89 |
| Savella | 34 | $8,604 | $253 |
| Voltaren | 34 | $6,528 | $192 |
| Uloric | 11 | $5,921 | $538 |
| Leflunomide | 38 | $3,937 | $104 |
| Prednisone | 202 | $3,683 | $18 |
| Duloxetine | 15 | $2,786 | $186 |
| Gabapentin | 92 | $2,694 | $29 |
| Tramadol Hcl-Acetaminophen | 18 | $1,857 | $103 |
| Meperidine | 12 | $1,609 | $134 |
| Oxycodone-Acetaminophen | 16 | $1,535 | $96 |
| Allopurinol | 47 | $962 | $20 |
| Tramadol | 69 | $819 | $12 |
| Cyclobenzaprine | 22 | $802 | $36 |
| Oxycodone Hcl-Aspirin | 11 | $778 | $71 |
| Azathioprine | 11 | $756 | $69 |
| Methylprednisolone | 13 | $580 | $45 |
| Leucovorin | 14 | $546 | $39 |
| Acetaminophen-Codeine | 12 | $537 | $45 |
| Alendronate | 45 | $487 | $11 |
| Zolpidem | 23 | $407 | $18 |
| Eszopiclone | 12 | $302 | $25 |
| Warfarin | 12 | $191 | $16 |
| Trazodone | 11 | $156 | $14 |
| Meloxicam | 19 | $115 | $6 |
| Insulin | 22 | $62 | $3 |
2014: 35 drugs
| Enbrel | 37 | $157,754 | $4,264 |
| Humira | 51 | $144,434 | $2,832 |
| Orencia | 24 | $64,966 | $2,707 |
| Forteo | 35 | $55,437 | $1,584 |
| Celebrex | 79 | $36,391 | $461 |
| Lidoderm | 20 | $20,462 | $1,023 |
| Lidocaine | 31 | $19,596 | $632 |
| Oxycontin | 24 | $14,774 | $616 |
| Hydrocodone-Acetaminophen | 190 | $12,805 | $67 |
| Methotrexate | 145 | $12,436 | $86 |
| Colcrys | 21 | $10,923 | $520 |
| Hydroxychloroquine Sulfate | 218 | $10,263 | $47 |
| Voltaren | 42 | $8,200 | $195 |
| Lyrica | 17 | $6,374 | $375 |
| Uloric | 18 | $6,262 | $348 |
| Savella | 21 | $4,211 | $201 |
| Duloxetine | 14 | $3,626 | $259 |
| Prednisone | 176 | $3,460 | $20 |
| Gabapentin | 43 | $2,406 | $56 |
| Tramadol Hcl-Acetaminophen | 32 | $2,267 | $71 |
| Tramadol | 102 | $1,766 | $17 |
| Leflunomide | 43 | $1,755 | $41 |
| Fentanyl | 13 | $1,653 | $127 |
| Oxycodone-Acetaminophen | 15 | $1,112 | $74 |
| Acetaminophen-Codeine | 27 | $728 | $27 |
| Cyclobenzaprine | 15 | $606 | $40 |
| Azathioprine | 14 | $552 | $39 |
| Alendronate | 43 | $522 | $12 |
| Allopurinol | 40 | $508 | $13 |
| Nabumetone | 19 | $468 | $25 |
| Carisoprodol | 13 | $406 | $31 |
| Naproxen | 11 | $221 | $20 |
| Bd Ultra-Fine Pen Needle | 12 | $148 | $12 |
| Methotrexate | 12 | $105 | $9 |
| Insulin | 14 | $44 | $3 |
2013: 32 drugs
| Enbrel | 34 | $135,849 | $3,996 |
| Humira | 41 | $105,740 | $2,579 |
| Forteo | 34 | $46,219 | $1,359 |
| Celebrex | 72 | $29,261 | $406 |
| Lidoderm | 34 | $24,943 | $734 |
| Oxycontin | 25 | $15,084 | $603 |
| Methotrexate | 128 | $11,473 | $90 |
| Hydroxychloroquine Sulfate | 217 | $6,579 | $30 |
| Colcrys | 16 | $6,541 | $409 |
| Hydrocodone-Acetaminophen | 188 | $5,636 | $30 |
| Lyrica | 15 | $5,614 | $374 |
| Savella | 21 | $4,246 | $202 |
| Cymbalta | 14 | $4,183 | $299 |
| Gabapentin | 51 | $3,973 | $78 |
| Uloric | 13 | $3,657 | $281 |
| Tramadol Hcl-Acetaminophen | 46 | $3,631 | $79 |
| Voltaren | 26 | $3,155 | $121 |
| Fentanyl | 15 | $2,298 | $153 |
| Tramadol | 76 | $1,824 | $24 |
| Prednisone | 103 | $1,588 | $15 |
| Leflunomide | 24 | $1,544 | $64 |
| Zolpidem Tartrate Er | 13 | $1,341 | $103 |
| Nabumetone | 27 | $844 | $31 |
| Etodolac | 12 | $735 | $61 |
| Azathioprine | 15 | $601 | $40 |
| Alendronate | 45 | $558 | $12 |
| Sulindac | 11 | $479 | $44 |
| Carisoprodol | 16 | $464 | $29 |
| Acetaminophen-Codeine | 18 | $426 | $24 |
| Allopurinol | 30 | $399 | $13 |
| Cyclobenzaprine | 15 | $295 | $20 |
| Meloxicam | 18 | $226 | $13 |
Money from drug and device companies
$85 in 2025
| 2025 | 1 | 4 | None | $85 |
| 2022 | 2 | 2 | None | $187 |
| 2020 | 1 | 1 | None | $81 |
| 2019 | 1 | 2 | None | $76 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Uplizna | $85 | 4 payments
|
See all 4 published payments
| Amgen | Meals · 2025-09-12 | Uplizna | $28 |
| Amgen | Meals · 2025-08-27 | Uplizna | $27 |
| Amgen | Meals · 2025-08-25 | Uplizna | $14 |
| Amgen | Meals · 2025-08-20 | Uplizna | $16 |
See earlier years (2022, 2020, 2019)
2022: $187
| Abbvie | Rinvoq | $103 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Saphnelo | $84 | 1 payment
|
2020: $81
| Amgen | Enbrel | $81 | 1 payment
|
2019: $76
| Amgen | Enbrel | $76 | 2 payments
|
Professional record
- NPI
- 1497839864
- Licence
- CA G64264California G64264: Current · expires 2027-12-31
- Trained
- Northeastern Ohio University College of Medicine, 1987
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X); Internal medicine (207R00000X)
- Mailing address
- 50 E Hamilton Ave Ste 200, Campbell, CA, 95008
- NPI first listed
- 2006-10-24
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.